Latest Innovative Drug Approvals in China 2026
This article highlights the latest innovative drug approvals in China 2026, covering drug names, indications, pharmaceutical companies, and approval dates across multiple therapeutic areas. It is regularly updated to reflect new developments in China’s pharmaceutical market.
In 2026, pharmaceutical innovation and new drug approvals in China continued to advance, covering a wide range of therapeutic areas, including oncology, immune-mediated diseases, rare diseases, metabolic disorders, and neurological conditions.
From targeted cancer therapies, antibody-based drugs, and cell therapies to treatments for chronic and rare diseases, the latest approvals reflect an increasingly diverse pharmaceutical landscape in China.
DengYueMed has compiled this overview of the latest innovative drug approvals in China 2026, based on updates from NMPA, to help global pharmaceutical companies, drug distributors, and healthcare institutions stay informed about new drug developments and approval trends in the Chinese market.
| No. | English Generic Name | Chinese Generic Name | Indication | Pharmaceutical Company | Approval Date |
|---|---|---|---|---|---|
| 1 | Sonrotoclax | 索托克拉 | Relapsed or refractory mantle cell lymphoma (MCL) | BeOne Pharmaceutical (Suzhou) Co. Ltd. | 2026-01-06 |
| 2 | Plozasiran Sodium | 普乐司兰钠 | Triglyceride reduction in adults with familial chylomicronemia syndrome (FCS) | Arrowhead Pharmaceuticals, Inc. | 2026-01-07 |
| 3 | Retlirafusp alfa | 瑞拉芙普α | Advanced gastric or gastroesophageal junction adenocarcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd | 2026-01-07 |
| 4 | Olorigliflozin | 奥洛格列净 | Glycemic control in adults with type 2 diabetes | YiChang HEC ChangJiang Pharmaceutical Co., Ltd. | 2026-01-16 |
| 5 | Libevitug | 立贝韦塔单抗 | Chronic hepatitis D virus (HDV) infection, with or without compensated cirrhosis | Huahui Health Ltd. | 2026-01-23 |
| 6 | Ecnoglutide | 埃诺格鲁肽 | Glycemic control in adults with type 2 diabetes | Hangzhou Sciwind Biosciences Co., Ltd. | 2026-01-30 |
| 7 | Amdokitug (SSGJ-608) | 安沐奇塔单抗 | Moderate-to-severe plaque psoriasis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2026-02-13 |
| 8 | Rovadicitinib | 罗伐昔替尼 | Myelofibrosis-related splenomegaly or symptoms | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | 2026-02-28 |
| 9 | Loncipoetin alfa | 罗赛促红素α | Anemia associated with chronic kidney disease | 3SBio, Inc | 2026-03-19 |
| 10 | Depemokimab | 德莫奇单抗 | Maintenance treatment of severe eosinophilic asthma in adults and adolescents aged 12 years and older | GlaxoSmithKline Trading Services Limited | 2026-03-27 |
| 11 | Technetium (99mTc) Rectegatide Pecixetan | 锝[99mTc]佩昔瑞特加肽 | Adjunctive assessment of regional lymph node metastasis in suspected lung cancer | Foshan Rui Diao Pharmaceutical Co Ltd | 2026-04-02 |
| 12 | Higenamine Hydrochloride | 去甲乌药碱 | Pharmacological stress imaging for cardiac function assessment | Zhuhai Rundu Pharmaceutical Co., Ltd | 2026-04-02 |
| 13 | Savolitinib | 塞伐艾替尼 | HER2-mutated advanced non-small cell lung cancer (NSCLC) | Bayer HealthCare Pharmaceuticals Inc. | 2026-04-21 |
| 14 | Andamertinib Benzoate | 安达艾替尼 | EGFR exon 20 insertion-mutated lung cancer | Avistone Biotechnology Co., Ltd. | 2026-04-30 |
| 15 | Bezacitinib | 贝泽昔替尼 | Intermediate-2 or high-risk myelofibrosis | Hangzhou Bangshun Pharmaceutical Co., Ltd | 2026-04-30 |
| 16 | Firsekibart | 伏欣奇拜单抗 | Acute gouty arthritis in adults with limited treatment options | Changchun GeneScience Pharmaceuticals Co., Ltd | 2026-04-30 |
| 17 | Fazamorexant | 法赞雷生 | Insomnia in adults | Jiangsu Haici Biological Pharmaceutical Co., Ltd. | 2026-05-21 |
| 18 | Nipocalimab | 尼卡利单抗 | AChR- or MuSK-antibody-positive generalized myasthenia gravis in adults and adolescents aged 12 years and older | Janssen-Cilag International NV | 2026-05-21 |
| 19 | Ruzinurad Sodium | 鲁兹诺雷 | Gout with hyperuricemia | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 2026-05-28 |
| 20 | Donaperminogene seltoplasmid | 塞多明基 | Limb ulcers caused by severe lower limb ischemia | Beijing Northland Biotech Co., Ltd | 2026-05-28 |
| 21 | Anbenitamab | 安尼妥单抗 | HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma | Shanghai JMT Biological Technology Co Ltd | 2026-05-28 |
| 22 | Rocbrutinib | 洛布替尼 | Refractory mantle cell lymphoma (MCL) in adults | Guangzhou Lupeng Pharmaceutical Co., Ltd | 2026-06-04 |
| 23 | Eratrectinib | 安瑞曲替尼 | Solid tumors in adults and adolescents aged 12 years and older | JIANGSU VCARE PHARMATECH CO.,LTD | 2026-06-04 |
| 24 | Sibeprenlimab | 斯贝利单抗 | Proteinuria in adults with primary IgA nephropathy (IgAN) | Otsuka Pharmaceutical Co., Ltd. | 2026-06-04 |
| 25 | Bemiltenase alfa | 波米泰酶α | Bleeding episodes in adults with hemophilia A or B | Jiangsu BioJeTay Biotechnology Co., Ltd | 2026-06-04 |
| 26 | Gumokimab | 古莫奇单抗 | Moderate-to-severe plaque psoriasis | Akeso, Inc. | 2026-06-11 |
| 27 | Clesrovimab | 克莱罗韦单抗 | Prevention of RSV lower respiratory tract disease in newborns and infants entering their first RSV season | Merck Sharp & Dohme B.V. | 2026-06-11 |
| 28 | Conteltinib | 康特替尼 | Non-small cell lung cancer (NSCLC) | Shouyao Holdings Co., Ltd | 2026-06-11 |
| 29 | Lannocopan | 兰诺可泮 | Paroxysmal nocturnal hemoglobinuria (PNH) | Createrna | 2026-06-11 |
| 30 | Imlunestrant Tosylate | 依仑司群 | ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, alone or with abemaciclib | Eli Lilly Nederland B.V. | 2026-06-22 |
| 31 | Peceleganan | 培来加南 | Wound infections in first-degree or superficial second-degree burns caused by specified bacteria | ProteLight Pharmaceuticals (Jiangsu) Co., Ltd | 2026-06-22 |
| 32 | Silevimig | 斯乐韦米单抗 | Passive immunization following rabies virus exposure in adults | Chongqing Genrix Biopharmaceutical Co., Ltd | 2026-06-22 |
| 33 | Satricabtagene Autoleucel | 舒瑞基奥仑赛 | CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of therapy | Kaixing Life Technology (Shanghai) Co., Ltd | 2026-06-22 |
| 34 | Izalontamab Brengitecan | 伦康依隆妥单抗 | Recurrent or metastatic nasopharyngeal carcinoma | Baili Bio Chengdu Pharmaceutical Co. Ltd. | 2026-06-22 |
| 35 | Anivecrine Succinate | 安维吖啶 | Symptomatic treatment of mild-to-moderate Alzheimer’s disease | Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd | 2026-06-23 |
| 36 | Amogammadex Sodium | 阿更葡糖钠 | Reversal of rocuronium-induced neuromuscular blockade | Zhejiang Xianju Pharmaceutical Co., Ltd | 2026-07-14 |
| 37 | Oveporexton | 奥普雷顿 | Narcolepsy type 1 in adults and adolescents aged 16 years and older | Takeda GmbH | 2026-07-23 |
| 38 | Ciprocopan Succinate | 思普可泮 | PNH in adults who have not previously received complement inhibitors | Haisco Pharmaceutical Group Co., Ltd | 2026-07-23 |
| 39 | Iscartrelvir Hydrochloride | 伊司特韦 | Mild-to-moderate COVID-19 in adults | Taizhou Four Dimensional Chemical Factory | 2026-07-29 |
| 40 | Insulin Sudelidec | 舒地胰岛素 | Type 2 diabetes in adults | Jiangsu Hengrui Pharmaceuticals Co., Ltd | 2026-07-29 |
| 41 | Recibokibart | 瑞西奇拜单抗 | Flares of generalized pustular psoriasis in adults | Zhejiang Huahai Pharmaceutical Co.,Ltd. | 2026-07-29 |
| 42 | Tinengotinib | 恩戈替尼 | Previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TransThera Sciences (Nanjing), Inc | 2026-08-04 |
| 43 | Felzartamab | 菲泽妥单抗 | Multiple myeloma after at least one prior line of therapy, in combination with lenalidomide and dexamethasone | TJ Biopharma Hangzhou Co Ltd | 2026-08-11 |
| 44 | Anflekitug | 安弗利奇塔单抗 | Acute gouty arthritis in adults with limited treatment options | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2026-08-18 |
| 45 | Licancopan | 立康可泮 | PNH in adults who have not previously received complement inhibitors | Chengdu Shengdi Pharmaceutical Co., Ltd | 2026-08-18 |
| 46 | Asandeutertinib | 氘申艾替尼 | First-line treatment of advanced NSCLC with EGFR mutations and CNS metastases | TYK Medicines, Inc | 2026-08-25 |
| 47 | Icotrokinra | 伊可白滞素 | Moderate-to-severe plaque psoriasis in eligible adults and pediatric patients | Janssen-Cilag International NV | 2026-08-25 |
| 48 | Fanregratinib | 凡瑞格拉替尼 | Previously treated advanced intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement | Hutchison MediPharma Ltd. | 2026-08-25 |
| 49 | Velinotamig | 纬利妥米单抗 | Relapsed or refractory multiple myeloma after at least three prior lines of therapy | Chongqing Genrix Biopharmaceutical Co., Ltd | 2026-08-25 |
| 50 | Lecankitug | 莱康奇塔单抗 | Moderate-to-severe plaque psoriasis in adults | Livzon Mabpharm Inc | 2026-08-25 |
| 51 | Rilzabrutinib | 利扎布替尼 | Persistent or chronic immune thrombocytopenia (ITP) in adults with inadequate response or intolerance to prior therapy | Genzyme Corporation | 2026-09-02 |
| 52 | Etripamil | 艾曲帕米 | Acute episodes of paroxysmal supraventricular tachycardia (PSVT) in adults | Milestone Pharmaceuticals Inc. | 2026-09-02 |
| 53 | Clulevibart | 库莱韦拜单抗 | Prevention of RSV lower respiratory tract disease in eligible newborns and infants | Ruiyang Shandong Biopharmaceutical Co. Ltd. | 2026-09-02 |
| 54 | Retavibart | 芮特韦拜单抗 | Prevention of RSV lower respiratory tract disease in newborns and infants entering their first RSV season | Trinomab Biotech Co., Ltd | 2026-09-02 |
| 55 | Iberdomide | 艾泊度胺 | Multiple myeloma after at least one prior line of therapy, in combination with daratumumab and dexamethasone | Bristol-Myers Squibb Pharma EEIG | 2026-09-29 |
| 56 | Batoclimab | 巴托利单抗 | AChR antibody-positive generalized myasthenia gravis (gMG) in adults | DRAGON MERIT HOLDINGS LIMITED | 2026-10-22 |
| 57 | Asundexian | 阿舒克森 | Reduction of stroke risk after non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) | Bayer | 2026-10-26 |
About DengYueMed: A China Pharmaceutical Wholesaler
DengYueMed is a Hong Kong-based China pharmaceutical wholesaler specializing in pharmaceutical import and export, drug procurement, and supply chain services. It serves global pharmaceutical companies, distributors, wholesalers, hospitals, pharmacies, and research institutions.
DengYueMed provides access to pharmaceutical resources from China, including innovative drugs, generics, specialty medicines, and conventional medicines.
Its services include sourcing, procurement coordination, import and export agency, customs clearance, quality inspection, logistics tracking, and after-sales support, covering prescription, OTC, and cold-chain medicines.
By tracking developments such as the latest innovative drug approvals in china 2026 and the China rare disease drug catalog, DengYueMed helps international partners explore China’s pharmaceutical resources and identify potential business cooperation opportunities.
Explore China Pharmaceutical Export Solutions
FAQ about Latest Innovative Drug Approvals in China 2026
What Are the Latest Innovative Drug Approvals in China in 2026?
The latest innovative drug approvals in China in 2026 include new therapies across oncology, immunology, rare diseases, metabolic disorders, and other therapeutic areas.
Which Authority Approves New Drugs in China?
The National Medical Products Administration (NMPA) is China’s primary authority responsible for drug registration and approval.
How Can I Check Whether a Drug Is Approved in China?
You can check drug approval information through the NMPA’s official website and its drug registration and public information databases.
What Types of Innovative Drugs Are Approved in China?
China’s innovative drug approvals cover various categories, including targeted therapies, monoclonal antibodies, biologics, cell therapies, and other novel treatments.
How Can International Companies Access Pharmaceutical Resources from China?
International companies can work with qualified China pharmaceutical wholesalers such as DengYueMed for drug sourcing, procurement coordination, import and export agency, and supply chain support.
